A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma

Trial Profile

A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Defactinib (Primary) ; VS 5584 (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Sponsors Verastem
  • Most Recent Events

    • 03 Jan 2017 Status changed from active, no longer recruiting to discontinued.
    • 19 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 10 Sep 2015 According to a Verastem media release, data from this study will be presented at the 16th World Conference on Lung Cancer (WCLC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top